1 day Ago By ABMN Staff
Corvus Pharmaceuticals ( NASDAQ:CRVS – Get Free Report ) had its price objective increased by investment analysts at LADENBURG THALM/SH SH from $12.00 to $21.00 in a report issued on Monday, Benzinga reports.
The firm currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price objective suggests a potential upside of 281.82% from the company’s current price.
Separately, StockNews.com upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 13th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock.
According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.83.
Get Our Latest Stock Analysis on Corvus Pharmaceuticals Corvus Pharmaceuticals Price Performance Corvus Pharmaceuticals ( NASDAQ:CRVS – Get Free Report ) last issued its earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.
12) by $0.05. During the same period in the previous year, the business posted ($0.
14) earnings per share. On average, research analysts anticipate that Corvus Pharmaceuticals will post -0.45 EPS for the current year.
Institutional Inflows and Outflows Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $44,000. Marshall Wace LLP purchased a new stake in Corvus Pharmaceuticals in the second quarter worth about $136,000.
Towerview LLC raised its stake in shares of Corvus Pharmaceuticals by 4.6% in the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after buying an additional 17,500 shares during the period.
Vanguard Group Inc. lifted its position in shares of Corvus Pharmaceuticals by 10.6% during the 1st quarter.
Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after buying an additional 142,724 shares in the last quarter. Finally, Point72 Asset Management L.
P. bought a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $10,855,000. Hedge funds and other institutional investors own 46.
64% of the company’s stock. About Corvus Pharmaceuticals ( Get Free Report ) Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
See Also Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
